Seres Therapeutics Inc
NASDAQ:MCRB

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
NASDAQ:MCRB
Watchlist
Price: 0.9905 USD 8.19% Market Closed
Market Cap: 169.1m USD
Have any thoughts about
Seres Therapeutics Inc?
Write Note

Seres Therapeutics Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Seres Therapeutics Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Seres Therapeutics Inc
NASDAQ:MCRB
Other Non-Cash Items
-$87m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Non-Cash Items
$7B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Non-Cash Items
-$419m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Non-Cash Items
$742.4m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Non-Cash Items
$480.1m
CAGR 3-Years
24%
CAGR 5-Years
-6%
CAGR 10-Years
4%
No Stocks Found

Seres Therapeutics Inc
Glance View

Market Cap
168.6m USD
Industry
Biotechnology

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).

MCRB Intrinsic Value
0.5699 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Seres Therapeutics Inc's Other Non-Cash Items?
Other Non-Cash Items
-87m USD

Based on the financial report for Sep 30, 2024, Seres Therapeutics Inc's Other Non-Cash Items amounts to -87m USD.

Back to Top